SELLAS Life Sciences Group, Inc. SEC filings SLS
SELLAS Life Sciences Group, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Apr 21, 2011. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 27, 2026 | — |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 31, 2026 | — |
| 8-K |
Current report
Results of operations, Other events
|
Jul 27, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| S-8 | Employee stock plan registration | Jun 16, 2026 | — |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 24, 2026 | — |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 16, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 27, 2026 | — |
| S-3ASR | Automatic shelf registration | Mar 20, 2026 | — |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Mar 11, 2026 | Mar 11, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 30, 2026 | — |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 8, 2026 | Jan 7, 2026 |
| 4 | Insider transaction | Dec 5, 2025 | Dec 3, 2025 |
| 4 | Insider transaction | Dec 5, 2025 | Dec 3, 2025 |
| 4 | Insider transaction | Dec 5, 2025 | Dec 3, 2025 |
| EFFECT | Filing | Nov 25, 2025 | — |
| CORRESP | Letter to the SEC | Nov 21, 2025 | — |
| 4 | Insider transaction | Nov 21, 2025 | Nov 19, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 14, 2025 | — |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 424B5 | Prospectus supplement | Oct 27, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Oct 27, 2025 | Oct 24, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 17, 2025 | — |
| S-3 | Shelf registration | Oct 10, 2025 | — |
| 8-K |
Current report
Material agreement
|
Oct 3, 2025 | Oct 1, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 11, 2025 | Sep 10, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| S-8 | Employee stock plan registration | Aug 12, 2025 | — |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 29, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Jun 10, 2025 | — |
| 8-K |
Current report
Auditor change
|
Jun 6, 2025 | Jun 3, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 30, 2025 |
| 4 | Insider transaction | May 22, 2025 | May 22, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| ARS | Annual report to shareholders | Apr 23, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 424B5 | Prospectus supplement | Jan 29, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jan 29, 2025 | Jan 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 23, 2025 | Jan 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 16, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 10, 2024 | Dec 10, 2024 |
| 4 | Insider transaction | Dec 5, 2024 | Dec 4, 2024 |
| 4 | Insider transaction | Dec 5, 2024 | Dec 4, 2024 |
| 4 | Insider transaction | Dec 5, 2024 | Dec 4, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 8, 2024 | — |
| 8-K |
Current report
Material agreement
|
Oct 4, 2024 | Oct 3, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 1, 2024 | Jul 30, 2024 |
| 424B5 | Prospectus supplement | Aug 1, 2024 | — |
| 3 | Initial insider ownership | Jun 27, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| EFFECT | Filing | May 1, 2024 | — |
| EFFECT | Filing | May 1, 2024 | — |
| ARS | Annual report to shareholders | Apr 30, 2024 | Dec 31, 2023 |
| CORRESP | Letter to the SEC | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 29, 2024 | — |
| S-3/A | Filing | Apr 29, 2024 | — |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 20, 2024 |
| UPLOAD | Letter from the SEC | Apr 2, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2024 | — |
| D | Filing | Mar 29, 2024 | — |
| S-3 | Shelf registration | Mar 28, 2024 | — |
| S-3 | Shelf registration | Mar 28, 2024 | — |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 10-K | Annual report | Mar 28, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Mar 28, 2024 | Mar 28, 2024 |
| 424B5 | Prospectus supplement | Mar 18, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Mar 15, 2024 | Mar 15, 2024 |
| 8-K |
Current report
Other events
|
Mar 11, 2024 | Mar 11, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Mar 8, 2024 | Mar 6, 2024 |
| 8-K |
Current report
Other events
|
Mar 5, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 16, 2024 | Feb 14, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 7, 2024 | — |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| 4 | Insider transaction | Jan 25, 2024 | Jan 22, 2024 |
| S-8 | Employee stock plan registration | Jan 19, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jan 8, 2024 | Jan 4, 2024 |
| 424B5 | Prospectus supplement | Jan 5, 2024 | — |
| 424B5 | Prospectus supplement | Jan 4, 2024 | — |
| 8-K |
Current report
Agreement ended
|
Jan 3, 2024 | Jan 2, 2024 |
| 8-K |
Current report
Other events
|
Dec 22, 2023 | Dec 19, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 13, 2023 | Dec 11, 2023 |
| 4 | Insider transaction | Dec 8, 2023 | Dec 6, 2023 |
| 4 | Insider transaction | Dec 8, 2023 | Dec 6, 2023 |
| 4 | Insider transaction | Dec 8, 2023 | Dec 6, 2023 |
| 4 | Insider transaction | Dec 8, 2023 | Dec 6, 2023 |
| 8-K |
Current report
Listing notice
|
Dec 8, 2023 | Dec 6, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 424B5 | Prospectus supplement | Nov 1, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
Oct 31, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Other events
|
Oct 16, 2023 | Oct 16, 2023 |
| 8-K |
Current report
Other events
|
Oct 13, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2023 | Jun 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 1, 2023 | May 30, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 20, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2023 | Jun 20, 2023 |
| S-8 | Employee stock plan registration | Mar 16, 2023 | — |
| 8-K |
Current report
Results of operations
|
Mar 16, 2023 | Mar 16, 2023 |
| 10-K | Annual report | Mar 16, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 1, 2023 | Feb 28, 2023 |
| 424B5 | Prospectus supplement | Feb 24, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
Feb 24, 2023 | Feb 23, 2023 |
| 424B5 | Prospectus supplement | Feb 23, 2023 | — |
| 8-K |
Current report
Results of operations
|
Feb 23, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 6, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 4 | Insider transaction | Feb 3, 2023 | Feb 2, 2023 |
| 8-K |
Current report
Other events
|
Dec 13, 2022 | Dec 13, 2022 |
| 4 | Insider transaction | Dec 5, 2022 | Dec 5, 2022 |
| 4 | Insider transaction | Dec 5, 2022 | Dec 5, 2022 |
| 4 | Insider transaction | Dec 5, 2022 | Dec 5, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 15, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 14, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2022 | Sep 15, 2022 |
| 4 | Insider transaction | Aug 16, 2022 | Aug 13, 2022 |
| 3 | Initial insider ownership | Aug 16, 2022 | Aug 13, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 16, 2022 | Aug 13, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 8, 2022 |
| S-8 | Employee stock plan registration | May 12, 2022 | — |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 6, 2022 | Apr 6, 2022 |
| 424B5 | Prospectus supplement | Apr 1, 2022 | — |
| 8-K |
Current report
Material agreement, Other events
|
Apr 1, 2022 | Mar 31, 2022 |
| 424B5 | Prospectus supplement | Mar 31, 2022 | — |
| 8-K |
Current report
Material agreement, Other events
|
Mar 31, 2022 | Mar 30, 2022 |
| 10-K | Annual report | Mar 31, 2022 | Dec 31, 2021 |
| 4 | Insider transaction | Mar 15, 2022 | Mar 14, 2022 |
| 3 | Initial insider ownership | Mar 14, 2022 | Mar 14, 2022 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1390478
- Former names
- GALENA BIOPHARMA, INC. (until Dec 15, 2017); Galena Biopharma, Inc. (until Dec 15, 2017); RXI PHARMACEUTICALS CORP (until Sep 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.